In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Amgen’s current price trades 15% below high-confidence fair value, indicating potential undervaluation with upside toward $535. Strong profitability and growth offset low leverage and moderate liquidity, supporting intrinsic valuation near $820 in Monte Carlo’s base case. High volatility and 20% downside risk highlight notable investment uncertainty.